Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.55 |
| ▸ | NQO2 | P16083 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606041 | 0.88 | NQO2 (0.50) | TERTNQO2LMNAKDM4EPOLB | |
| SCHEMBL13701566 | 0.84 | LMNA (0.58) | TERTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6607044 | 0.83 | NQO2 (0.52) | TERTNQO2LMNAKDM4EPOLB | |
| SCHEMBL6617731 | 0.81 | TERT (0.51) | TERTNQO2LMNANCF1ALDH1A1 | |
| SCHEMBL6605394 | 0.81 | NUDT1 (0.44) | TERTNQO2LMNAKDM4EPOLB | |
| SCHEMBL6600747 | 0.81 | TERT (0.54) | TERTNQO2LMNANCF1ALDH1A1 | |
| SCHEMBL5849336 | 0.80 | TERT (0.64) | TERTNQO2MEN1MMP1MMP9 | |
| SCHEMBL6603060 | 0.80 | TERT (0.38) | TERTNQO2LMNAKDM4EPOLB | |
| SCHEMBL6846673 | 0.79 | CYP1A2 (0.57) | TERTNQO2LMNAKDM4EPOLB | |
| SCHEMBL3235863 | 0.79 | NCF1 (0.63) | TERTNQO2LMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070232572-A1 | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent | AVENTIS PHARMA S.A. (FR) | 2007-10-04 | — | — | US | disclosed |
| US-20060199840-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| US-6995175-B2 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2006-02-07 | — | — | US | disclosed |
| EP-1603898-A2 | CHEMICAL DERIVATIVES BINDING VERY SPECIFICALLY WITH G-QUADRUPLEX DNA STRUCTURES AND USE THEREOF AS A SPECIFIC ANTI-CANCER AGENT | Aventis Pharma S.A. (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| WO-2004072027-A2 | CHEMICAL DERIVATIVES BINDING VERY SPECIFICALLY WITH G-QUADRUPLEX DNA STRUCTURES AND USE THEREOF AS A SPECIFIC ANTI-CANCER AGENT | AVENTIS PHARMA S.A. (FR) | 2004-08-26 | — | — | WO | disclosed |
| US-20040138257-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMA S.A. (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMS S.A. | 2004-03-18 | — | — | US | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-6645964-B1 | 1,3,5-Triazine compounds substituted with aromatic N-heterocycle; anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1244650-B1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA SA (FR) | 2003-06-25 | — | — | EP | disclosed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | disclosed |
| CN-1402722-A | Arylamine derivatives and their use as anti-telomerase agents | AVENTIS PHARMA SA (FR) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002096903-A2 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
| EP-1244650-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001040218-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | TERT 43/4885NQO2 784/4885LMNA 2573/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | TERT 196/4885NQO2 101/4885LMNA 3046/4885 |
| US-20040138257-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | TERT 183/4885NQO2 101/4885LMNA 3138/4885 |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | TERT 168/4885NQO2 101/4885LMNA 3154/4885 |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | DPYD, NTPCR, NME1 | TERT 196/4885NQO2 101/4885LMNA 3046/4885 |
| US-20070232572-A1 | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent | DDX21, DNASE1L3, NTPCR | TERT 76/4885NQO2 112/4885LMNA 1585/4885 |
| US-20060199840-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | TERT 183/4885NQO2 101/4885LMNA 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.